Drug intelligence / Profile preview

NEO-201 CAR-M

Development stage: Preclinical
Lead developer: Precision Biologics
Modality: CAR-Macrophages → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Other Cell Types → Cell Therapies
Administration: Intravenous

Overview

NEO-201 CAR-M is an investigational chimeric antigen receptor macrophage (CAR-M) cell therapy being developed by Precision Biologics. The therapy involves engineering macrophages to express a chimeric antigen receptor (CAR) derived from the NEO-201 monoclonal antibody, which specifically targets truncated O-glycans. These truncated O-glycans are tumor-associated carbohydrate antigens (TACAs) that are highly expressed on various solid and hematologic malignancies but are absent in healthy tissues. By directing macrophages to recognize these specific glycans, NEO-201 CAR-M aims to induce targeted phagocytosis of tumor cells and stimulate a broader anti-tumor immune response within the tumor microenvironment. It is currently in preclinical development for the treatment of both solid and blood tumors.

Other names: NEO-201 CAR-macrophageNEO201 CAR-macrophageNEO 201 CAR-macrophageNEO-201 CAR-macrophage cell therapyNEO201 CAR-macrophage cell therapyNEO 201 CAR-macrophage cell therapy

Targets

Tumor-associated truncated core 1 O-glycan

Beyond the preview

Go deeper on NEO-201 CAR-M.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NEO-201 CAR-M.

Explore the full profile